Biotech | March 29, 2022
Dupixent is a star in Sanofi’s immunology strategy
Dupixent peak sales ambition raised to more than €13 billion
Dupixent peak sales ambition raised to more than €13 billion
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
As a partner with IRIA, the company had a significant booth presence on-ground during the conference.
The funding will accelerate the AI-driven healthcare company's market expansion into the global market and support new product development
New collaboration will help customers reach sustainability goals for high-performance Udel PSU polymers in demanding applications.
Veritaz has over 40 brands marketed across the acute and critical care therapeutic segments
Under the agreement, Technology Development Board and Bharat Biotech have pledged the support of Rs.200 crore each to create a continuous corpus of Rs.400 crores for the project
Vela Analytics can create concise, evidence-based in-house reports that help customers with the information to make timely, informed decisions about possible treatment options
It celebrated its 100th session as LPC-100 in association with Mundial Pharma
The fund will take equity positions in India-focused healthcare and life sciences-related companies
Subscribe To Our Newsletter & Stay Updated
